Good month. 40 papers. I think the main takeaway here is the buprenorphine waiver required for U.S. providers to treat their patients with buprenorphine – it needs to go. It is an archaic and absurd construct essentially invented by the US Supreme Court a century ago when the court decided “addiction is not a disease”.Read More
PubMed Update January 2019
We start out 2019 with 42 new papers. The overarching theme is fentanyl – with some useful data really starting to emerge. Also several addressing surveillance-type issues, which is still badly needed and exciting work. We’ve also got the standard naloxone papers and a few weird drugs (e.g. tramadol and kratom). 1) Drugs Most Frequently InvolvedRead More